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Background: We investigated the incidence and survival of non-cutaneous head and neck cancer (HNC)
after solid organ transplantation and identified prognostic factors impacting the outcome after treatment.
Methods: A retrospective analysis of patients who underwent solid organ transplantation in our institu-
tion between 1987 and 2012.
Results: Of 5255 organ transplant patients, 48 recipients (0.9%) developed HNC in the posttransplant fol-
low-up period. Liver transplant recipients showed the highest risk. Median follow-up of cancer patients
was 46.7 months (range 2.9–256.2 months). Three-year overall survival and disease free survival (DFS)
were 70% and 53%. Locoregional control was 67% and 48% at 3 and 5 years, respectively. Smoking and ini-
tial AJCC stage were two significant prognostic factors influencing DFS.
Conclusions: Non-cutaneous HNC is rare in transplant recipients, but slightly more common after liver
transplantation. Outcome after treatment is poor with locoregional recurrence being the main problem.
Screening of high risk groups might be relevant.
 2013 Elsevier Ltd. All rights reserved.Introduction
Due to long-term immunosuppression, transplanted patients
are often confronted with therapy induced complications. One of
the most important complications is the development of malignan-
cies. The incidences for several tumors are much higher in trans-
plant recipients when compared to the general population and
increase with longer duration of follow-up [1,2]. Tumors in the
head and neck area cover about 3.5–15% of all malignancies after
transplantation [3–5]. A large part of these head and neck cancers
(HNC) are squamous cell carcinomas (SCC) of the lip or oropharynx
[6–12]. The exact mechanism for carcinogenesis under immuno-
suppression remains unclear, however it is clearly a multifactorial
process [2]. Firstly, impaired immunosurveillance in itself canstimulate oncogenesis through independent processes. Secondly,
long-term immunosuppression also puts the patient at a higher
risk of being infected with an oncovirus like the human papilloma-
virus (HPV) or Epstein–Barr virus [2,13]. Thirdly the drugs used for
immunosuppression could also directly play a role. This is espe-
cially the case for calcineurin inhibitors (CNI) like cyclosporine
who potentially promote carcinogenesis through complex path-
ways involving increased angiogenesis, suppressed apoptosis of
damaged cells, DNA damage and altered DNA repair [1–3,14].
Other immunosuppressive agents, like MMF (mofetil mycopheno-
late) and more recently inhibitors of the mammalian target of rap-
amycin (mTOR), have an antiproliferative activity and might have a
more protective effect against some tumor types [1,2]. Finally the
impact of more ‘classical’ etiological factors should not be ne-
glected. The impact of tobacco exposure and the synergistic carcin-
ogenic effect of alcohol have long been demonstrated in the
general population. In transplant patients, tobacco and/or alcohol
also increase the risk of developing HNC (HR = 9.2; 95% CI 2.0–
42.0; p = 0.004) [4,6,8,12].
In general, principles of HNC treatment remain identical both in
the transplanted and non-transplanted population.Modifications of
the immunosuppression treatment are often recommendedce. Oral
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butmost experiences in the literature seem tonote aworse outcome
than in the general population. In general, the cancer progresses at a
faster rate in transplant recipients and is more refractory to treat-
ment, which explains the worse prognosis [4,15]. In addition, most
often, patients are diagnosed at an advanced stage of HNC (stage
III or IV), limiting the therapeutic options [4,6,12].
The goal of our study was to determine the incidence and sur-
vival of HNC after solid organ transplantation in our institute, to
compare this with the literature and to identify prognostic factors
impacting the outcome after treatment.Patients and methods
Study population
We conducted a retrospective search for all patients who under-
went an organ transplantation (kidney, liver, heart or lung) at the
University Hospitals Leuven and were diagnosed with HNC during
follow-up. We started by querying the databases of 4 different or-
gan transplantation departments: renal, heart, liver and lung,
respectively starting from November 1963, September 1987,
December 1989 and July 1991. All patients transplanted before
the start of the cancer registry database in January 1987 wereDatabase of solid or
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Oncol (2014), http://dx.doi.org/10.1016/j.oraloncology.2013.12.016excluded. Secondly, all these patients’ files were linked to our can-
cer registry data. We selected all patients who were diagnosed
with HNC during the period from January 1987 until November
2012, based on all relevant ICD10-codes (International Classifica-
tion of Diseases, 10th edition; C01-13, C30-32, C73, C75). Database
linkages were accomplished using a computer-based matching
algorithm, followed by a manual review of all the files of the pa-
tients selected. Cutaneous, sarcomas and hematologic malignan-
cies were excluded. This study was approved by the local
medical ethics committee.
Statistical analysis
All analyses were carried out using the software package Statis-
tica 11 (Tulsa, USA). Follow-up data were retrospectively col-
lected. The date of first locoregional recurrence, distant
metastasis and/or death was recorded. The closeout date for sur-
vival analysis was January 2013. Cumulative survival and tumor
control rates were calculated using the Kaplan–Meier product-lim-
it (actuarial) method. Due to small numbers of patients we were
not able to do statistical analysis relating differences in mean time
to diagnosis, organ distribution or mean age in comparison to the
general population. The influence of gender, transplanted organ,
AJCC stage (I–II vs. III–IV), T-stage (T1-2 vs. T3-4), N-stage (N0 vs.
N+), previous nicotine and alcohol use, treatment (radiotherapygan
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Table 1
Clinical data.
Clinical data No. (%)
Sex
Female 8 (16.7)
Male 40 (83.3)
C. Nelissen et al. / Oral Oncology xxx (2014) xxx–xxx 3vs. surgery and single vs. multiple modalities) and alteration of
immunosuppression medication on disease free survival (DFS)
after treatment for HNC was calculated using a log rank test. For
multivariate analysis a cox proportional hazard analysis was per-
formed. A p value of less than 0.05 was considered to be statisti-
cally significant.Age
Mean 57.6 years (range 37–
76.3 years)
Smoking
Active/Ex-smoker 32 (66.7)
Non-smoker 13 (27.1)
No data 3 (6.2)
Alcohol
Active/ex – abuse 23 (47.9)
No abuse 25 (52.1)
Stage classification
I 14 (29.2)
II 10 (20.8)
III 6 (12.5)
IV 17 (35.4)
Unknown 1 (2.1)
Treatment modalities (46 patients)
Primary surgery 21 (45.7)
Postoperative radiotherapy 8 (17.4)
Dose (Gy) 50–62 Gy
Definitive radiotherapy 19 (41.3)
Dose (Gy) 66–72 Gy
Definitive chemoradiotherapy 5 (10.9)
Dose 72 Gy
Cisplatin 1 (2.2)
Carboplatin 1 (2.2)
Cetuximab 3 (6.5)
Best supportive care 1 (2.2)
Indications of renal transplantation 27/48
Glomerular disease 15
Chronic renal insufficiency NOS 4
Tubulointerstitial disease 2
Hypertension/vascular disease 2
Diabetic nephropathy 2
Congenital kidney disease 2
Indications of liver transplantation 14/28
Alcoholic cirrhosis only 6
Hepatocellular carcinoma + alcoholic cirrhosis 3
Hepatocellular carcinoma + combined virus C and
alcoholic cirrhosis
1
Hepatocellular carcinoma + cryptogenic cirrhosis 1
Virus B related cirrhosis 1
Acute hepatic failure-(sub)fulminant hepatitis-
toxic (non drug)
1
Primary biliary cirrhosis 1
Indications of heart transplantation 5/28
Ischemic cardiomyopathy 2
Dilatated cardiomyopathy 3
Indications of lung transplantation 2/28
Terminal lung fibrosis secondary to dyskeratosis
congenita
1
Rheumatoid arthritis 1Results
Study population and tumor characteristics
A flowchart of the patient selection is depicted in Fig. 1. A total
of 5255 solid organ recipients were included in this analysis of
which 48 developed a noncutaneous HNC (0.9%). The patient and
tumor characteristics and treatment specifications are summarized
in Table 1. In the overall transplanted group 62.6% of the patients
were male and 37.4% were female. In our HNC study group 83.3%
of the patients were men. The mean follow-up after transplanta-
tion was 9.6 years (range 1 month – 24.9 years), 4.6 years (range
1 month – 21.5 years), 8.7 years (range 1 month – 43.5 years) and
5.8 years (range 1 month – 23 years) respectively for heart, lung,
renal and liver recipients. The mean time from transplantation to
cancer diagnosis was 7.8 years (range 2.4 months – 27.8 years).
The mean time from transplantation to cancer diagnosis was the
longest for kidney transplantations (122 months), in comparison
to liver (27 months), lung (56 months) and heart (100 months).
The subsite distribution of HNC is given in Table 2. Fourty-one
out of fourty-three mucosal malignancies were SCC. In one patient
with oral cavity cancer the pathology report showed adenomyo-
epithelioma. 3 patients developed malignancies of the parotid
gland: 1 primary parotid SCC, 1 muco-epidermoïd carcinoma and
one acinic cell carcinoma. One patient, who was a professional
wood worker, was diagnosed with an adenocarcinoma of intestinal
type in the ethmoid sinus. Finally two papillary cancers of the thy-
roid gland were found in the cohort. 2 patients were excluded from
further statistical analyses due to lacking information about the
treatment or follow-up. The remaining 46 patients were treated
for their malignancy in our institution or in another hospital.
More HNC was seen in liver transplant recipients in comparison
to other transplant groups: 14 of 965 patients (1.45%) were diag-
nosed with HNC. In comparison, 5 of 536 heart recipients
(0.93%), 27 of 3057 renal transplant patients (0.88%) and 2 of 697
(0.29%) lung recipients developed HNC.
Therapy
The largest part of our patients (21/46; 45.7%) received surgery
as a primary treatment modality, followed by definitive radiother-
apy or chemoradiotherapy (for stage III or IV). Postoperative radio-
therapy was applied in 8 cases following the international
recommendations (multiple lymph node metastasis (more than
one), T3 and T4 tumors, close margin, perineural growth, spidery
growth, positive resection margin and/or extracapsular spread).
The immunosuppressive therapy of 15 patients (31.3%) was ad-
justed during follow-up after treatment for HNC. Adjustments in-
cluded dose reductions, cessation of one drug from a combined
regimen and switching to an mTOR inhibitor [16]. Immunosup-
pression remained unchanged in 27 patients (56.3%) and for 6 pa-
tients (12.5%) there was no information about the
immunosuppressive treatment.
Outcome
The median follow-up after cancer diagnosis was 46.7 months
(range 2.9 months – 21.4 years). A locoregional control of 67%Please cite this article in press as: Nelissen C et al. Noncutaneous head and nec
Oncol (2014), http://dx.doi.org/10.1016/j.oraloncology.2013.12.016and 48% at respectively 3 and 5 years was seen. We noted distant
metastasis-free survival of 86% at 3 years and of 80% at 5 years.
Distant metastasis was seen at the lungs (5/48), bones (1/48), liver
(1/48). 3 patients developed diffuse metastases (lungs, liver and
bone). The disease free survival (DFS) rates were 53% and 38% at
3 and 5 years respectively. Overall survival rates were calculated:
70% at 3 years and 58% at 5 years (Fig. 2). Twenty-six% of the pa-
tients developed a second primary malignancy (stomach, lung, kid-
ney, prostate and skin cancer). At the last follow-up 15 patients
were free of disease and two patients were alive but developed dis-
ease recurrence. Thirty-one patients deceased. Of all patients whok cancer in solid organ transplant patients: Single center experience. Oral
Table 2
Subsite distribution of head and neck malignancies in transplant patients.
Subsite (%)
Oropharynx 43
Oral cavity 19
Larynx 15
Parotid gland 7
Hypopharynx 4
Thyroid gland 4
Nasal cavity 4
Ethmoid sinus 2
Nasal cavity 2
Table 3
Impact of different factors on DFS after univariate analysis.
Factor p-Value
Gender 0.72
Type of organ transplanted 0.476
T stage (T1/2 vs. T3/4) 0.013
N stage (N0 vs. N+) 0.49
AJCC stage (I–II vs. III–IV) 0.0087
Treatment modality (single vs. multi) 0.86
Primary radiotherapy vs. surgery 0.44
Immunosuppression adjustments 0.11
History of smoking 0.015
History of alcohol abuse 0.29
Table 4
Prognostic factors for DFS after multivariate analysis.
Factor Hazard ratio 95% CI p-Value
Non-smoker 0.23 0.06–0.82 0.02
AJCC stage I–II 0.23 0.07–0.74 0.01
IS adjustments 1.16 0.40–3.39 0.8
CI = confidence interval. IS = immunosuppression treatment.
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54.8% (17/31).
Univariate analysis (Table 3)
In univariate analysis, history of smoking (active and ex-smok-
ers vs. never smokers) (Fig. 3) and the AJCC-stage (American Joint
Committee on Cancer) (Fig. 4) were of statistical importance in
terms of prognostic impact on DFS. Between other variables and
DFS no correlation was noted.
Multivariate analysis (Table 4)
Multivariate analysis of prognostic factors for DFS was per-
formed. This showed no significant correlation between DFS and
adjustments of immunosuppression drugs. However, a significant
correlation with a history of smoking and with the initial stage
was seen.
Discussion
In this large solid organ transplantation population, 0.9% devel-
oped a non-cutaneous and non-hematologic malignancy in the
head and neck region. Two similar studies showed comparable re-
sults (0.5%, 0.6%) [3,4]. We found an unequal distribution of post-
transplant HNC between the different organs. Higher numbers of
HNC were seen in liver transplant recipients in comparison to
other transplant groups. However, the small numbers do not allow
us to make firm conclusions. Collett et al. [17] proved that the stan-
dardized incidence ratio (SIR) (10.0) for oral cavity cancer was
twice as high in liver transplant recipients compared to SIR’s found
in kidney, heart and lung recipients (4.2, 5.0, 5.0 and 5.0, respec-
tively). One of the logical explanations is ethyl abuse, which is an
important common risk factor for end-stage liver disease as well
as for HNC. In our cohort, 70% of liver transplant recipients had a
history of alcoholic liver cirrhosis. Alcoholic liver disease (ALD) is
the second most common cause of end-stage liver disease leadingPlease cite this article in press as: Nelissen C et al. Noncutaneous head and nec
Oncol (2014), http://dx.doi.org/10.1016/j.oraloncology.2013.12.016to an orthotopic liver transplant (OLT) [9]. In our institution, ALD
accounts for 26% of all liver transplant indications. In this specific
cirrhosis group, HNC is more frequent [6,7,9,17]. Incidences of oro-
pharyngeal cancer in ALD OLT patients vary between 1.12% and
16.7%. In OLT patients transplanted for other indications the inci-
dences of SCC in the oropharyngeal region are between 0% and
0.51% [7,9].
The mean age at cancer diagnosis in our study population was
57.6 years, which is slightly younger than the mean age at HNC
diagnosis in the general Belgian population [18] (62 years in males
and 63 years in females) but which is comparable with results from
the literature (mean age 48.2–60 years) [3,4,6,9,15,19]. Oropharyn-
geal carcinomas (48%) and oral cavity tumors (18%) are the most
frequent HNC in our unique patient group, followed by laryngeal
(15%) and salivary gland tumors (7%). This distribution is compara-
ble with data published earlier (>25%, 15–19% and 6% for orophar-
ynx, oral cavity, larynx, salivary gland and hypopharynx lesions
respectively) [3,7–10]. In the general Belgian population, laryngeal
tumors are the most frequent subsite in males whereas in females
tumors of the lip and the oral cavity are more common [18]. The
largest subgroup (35.4%) presented with stage IV disease. This is
comparable with HNC patients in the general Belgian population,
who also present with stage IV disease predominantly (32.4% for
men, 28.2% for women) [18].
Treatment modalities in our patient group were similar with
another single-center study, where surgery was needed in most
cases (84.6%), followed by radiotherapy (53.8%) and chemotherapy
(23.1%) [9]. Deeb et al. [3] states to be very cautious in administer-
ing platinum-based chemotherapeutics to immunosuppressed pa-
tients due to high potential side effects. They suggest cetuximab
(monoclonal antibody against EGFR) as systemic therapy. However
in our institution the decision on whether cisplatine-based chemo-
therapy is administered, is made on a global assessment of a pa-
tient’s health status (including renal function), not only on their
transplantation status. In our analysis, there was no superior treat-
ment modality determining the DFS. However, our study com-
prises a very diverse group of HNC, for which also in the general
population disease-specific treatment guidelines are followed.
Adjustments of immunosuppressive treatment, i.e. minimization,
discontinuation or switch to another type of drug, after diagnosis
of malignancy is often recommended in literature [2,4,14]. For
Kaposi sarcomas and recurrent skin cancers mTOR inhibitors are
increasingly seen as the cornerstone of the treatment in transplant
patients. The benefits associated with the use of these PSIs (prolif-
eration signal inhibitors)/mTOR inhibitors are yet to be established
in noncutaneous head and neck neoplasms. Some hypothesize that
because of the global antiproliferative effect of these drugs and
their ability to allow reduction or even withdrawal of CNI (calci-
neurin inhibitors) all patients with posttransplant malignancy
should be considered for conversion. Due to potential wound heal-
ing delay and the myelosuppressive effect, starting this medication
should be deferred until at least after surgery and chemotherapy
[2,14]. Yet in our study there was no significant difference in DFS
between patients whose immunosuppressive treatment was unal-
tered compared to those were it was reduced or changed. On the
contrary, patients whose immunosuppressive treatment was notk cancer in solid organ transplant patients: Single center experience. Oral
Fig. 2. LRC, DFS and OS.
Fig. 3. Impact of smoking on outcome of HNC after treatment in transplant
patients.
Fig. 4. Impact of initial stage on outcome of HNC after treatment in transplant
patients.
C. Nelissen et al. / Oral Oncology xxx (2014) xxx–xxx 5adjusted tended to have a better DFS. However, our patients’ files
might not contain full information regarding the exact adjustments
of the immunosuppressive treatment and it concerns a small, het-
erogeneous group. But again, recommendations made in literature
are made for all types of malignancy in the posttransplant period.
There is no evidence about adjustments to be made in patients
with HNC. Only one study reported on the correlation between
higher daily doses of immunosuppressive agents at HNC diagnosis
with significant decreased 2-year survival rates [4]. Uemura et al.
evaluated the use of the ‘‘ImmuKnow™’’ assay as a tool for guiding
safe manipulation of immunosuppression [20]. By measuring the
ATP level from CD4 + T cells, the immune status of patients with
a posttransplant malignancy treated by chemotherapy or radio-
therapy was monitored. A significant lower ImmuKnow™ level be-
fore and after malignancy treatment was found in the non-survivor
group, suggesting over-immunosuppression. They suggested that
the assay can possibly be useful in adjusting the immunosuppres-
sive therapy and defining the time of reintroduction of immuno-
suppression. Probably, modifications of immunosuppressionPlease cite this article in press as: Nelissen C et al. Noncutaneous head and nec
Oncol (2014), http://dx.doi.org/10.1016/j.oraloncology.2013.12.016should be made on a case-by-case basis, taking into account pa-
tient’s medical history and time interval since transplantation.
The literature does not provide recommendations for manage-
ment of HNC in this specific patient group, but since these patients
fare poorly treatment intensification might be considered.
The number of locoregional recurrences (LRR) found in our
study is lower than the 47.8% LRR within one year which was
found in the study of Preciado et al. [4]. We noted a distant metas-
tasis-free survival of 86% at 3 years and of 80% at 5 years. In other
words, only 17.4% of our patients developed distant metastasis. In
the cardiothoracic transplant group of Pollard et al. [10], 83.3% of
their patients with HNC became metastatic. In comparison, only
14.2% of our lung and heart transplant patients had metastatic dis-
ease. Three-year overall survival rates in our study population
were 70% at 3 years and 58% at 5 years. The single-center series
of liver transplantations, reported a 5-year survival rate after oro-
pharyngeal and laryngeal SCC between 37% and 41.5% [9,12]. Jain
et al. and Finkenstedt et al. report a one-year survival rate of
42.9% for oropharyngeal cancer in liver transplant recipients
[12,15]. In a long-term Dutch study of renal transplant patients,
5-year survival rates are markedly higher and up to 80% for oral
cavity SCC [11]. Thyroid tumors have 5-year survival rates reported
between 59% and 83.3%, clearly much higher than other carcino-
mas of the head and neck region [11,19]. In general, and this is also
the case for HNC in the general population, locoregional relapse is
the major cause of treatment failure in posttransplant HNC.
In this study, two significant prognostic factors influencing out-
come after treatment were found. A first prognostic factor is tobac-
co abuse. Transplant patients with HNC who have a history of
smoking (active or previous smokers) have a worse DFS compared
to never-smokers. Possibly in patients without a history of smok-
ing, HNC might be related to HPV (human papillomavirus) infec-
tion, which may explain the better outcome [21]. Since this is a
retrospective study, we could not confirm this hypothesis. Our pa-
tients are treated over a long period of time so for the most of them
there was no tumor tissue available for HPV testing. A meta-
analysis by Grulich et al. [13], reports a similarity of the pattern
of increased HPV-related cancers in HIV positive patients
and transplant recipients. SIR’s calculated for oral cavity and phar-
ynx carcinomas were 2.32 (95% CI 1.65–3.25) for the HIV cohort
and 3.23 (95% CI 2.40–4.35) for the transplant cohort. They
presume also a possible relation between larynx carcinomas andk cancer in solid organ transplant patients: Single center experience. Oral
6 C. Nelissen et al. / Oral Oncology xxx (2014) xxx–xxxHPV-infections and noted increased SIR’s in both populations.
There is no evidence in literature whether a pretransplant vaccina-
tion has an impact on preventing HPV-related SCC.
Additionally, the AJCC stage at moment of diagnosis had a sig-
nificant impact on DFS. Several other authors also noted significant
correlation between initial staging and survival (median survival,
41.4 months for stage I–II vs. 8.25 months for stage III–IV;
p = .008) [4,6,15].
Although an ear- nose- and throat examination (including
endoscopic evaluation) is often performed routinely as part of
the pretransplant investigations, patients are not screened regu-
larly after transplantation. Screening of the entire transplant pop-
ulation is not useful, however, studies such as ours could identify
particular subgroups of high risk patients that might benefit from
surveillance programs. Based on the relative higher number of
HNC in liver transplant patients in our study together with the
higher risk of HNC in smoking recipients described in literature,
(ex-) smokers and/or liver transplant recipients should be seen as
high risk group [6,8,12,14,15]. Subsequently, the frequency of
screening can be adapted to these important risk factors for malig-
nancy. Nevertheless, our data are based on a retrospective review
and a small patient group. Next to this, (cost-) effectiveness studies
supporting this recommendation are not available.
As this is a retrospective, single-institution analysis several
shortcomings should be taken into account. First, we looked at a
relatively small and heterogeneous patient population. The major-
ity of HNC were SCC’s, but also two papillary thyroid carcinomas,
one ethmoid sinus adenocarcinoma and two non-SCC parotid gland
tumors were included. For these latter tumor types, there is no eti-
ologic relation with smoking. Secondly, heterogeneous treatments
were administered, which is normal for the different types of HNC
but which makes statements about superiority of treatment diffi-
cult. Furthermore, we did not obtain detailed data about the exact
tobacco exposure in pack-years (PY). This way we cannot record
whether a history of ‘nonsignificant smoking’ (no history of smok-
ing or <20 PY or smoking cessation >10 years) before transplanta-
tion [6] is of prognostic importance. The same comment can be
made on alcohol (ab) use. Another limitation is the lack of com-
plete data on immunosuppression, partly due to changing proto-
cols during the whole study period, which also differ between
different departments. The possibility of a false negative result,
reporting bias and confounding by indication must be acknowl-
edged when comparing DFS between patients whose immunosup-
pressive treatment was unaltered compared to those were it was
reduced or changed. It is likely that the number of patients with
HNC is underestimated since we can never be sure whether all pa-
tient charts were up to date with information about HNC’s diag-
nosed in other institutions. However, we queried a database of
almost 6000 transplant patients and many of our results are favor-
ably comparable to data already published. Due to the rarity of this
disease, prospective validated trials are probably not feasible.
Conclusion
This retrospective analysis shows that HNC is rare in transplant
recipients, but slightly more common after liver transplantation.
Differences however are not statistically significant due to small
numbers of patients. There is no superior treatment defined. How-
ever since diagnosis of HNC in an early stage is of prognostic
importance and because locoregional recurrence is the main prob-
lem during follow-up, early detection and aggressive local treat-
ment are necessary. Screening in all transplant patients is notPlease cite this article in press as: Nelissen C et al. Noncutaneous head and nec
Oncol (2014), http://dx.doi.org/10.1016/j.oraloncology.2013.12.016feasible but subgroups of high-risk patients should be followed
closely.
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